264 related articles for article (PubMed ID: 20577964)
1. [Hereditary breast and ovarian cancer - indications for genetic testing, counseling and options for mutation carriers].
Bürki N
Ther Umsch; 2010 Jul; 67(7):359-66. PubMed ID: 20577964
[TBL] [Abstract][Full Text] [Related]
2. Familial breast and ovarian cancers.
Arai M; Utsunomiya J; Miki Y
Int J Clin Oncol; 2004 Aug; 9(4):270-82. PubMed ID: 15375703
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 genetic mutation and its link to ovarian cancer: implications for advanced practice nurses.
Brunsvold AN; Wung SF; Merkle CJ
J Am Acad Nurse Pract; 2005 Dec; 17(12):518-26. PubMed ID: 16293160
[TBL] [Abstract][Full Text] [Related]
4. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
Chompret A
J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
[TBL] [Abstract][Full Text] [Related]
5. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.
Scheuer L; Kauff N; Robson M; Kelly B; Barakat R; Satagopan J; Ellis N; Hensley M; Boyd J; Borgen P; Norton L; Offit K
J Clin Oncol; 2002 Mar; 20(5):1260-8. PubMed ID: 11870168
[TBL] [Abstract][Full Text] [Related]
6. Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information.
DiCastro M; Frydman M; Friedman I; Shiri-Sverdlov R; Papa MZ; Goldman B; Friedman E
Am J Med Genet; 2002 Aug; 111(2):147-51. PubMed ID: 12210341
[TBL] [Abstract][Full Text] [Related]
7. A new paradigm of genetic testing for hereditary breast/ovarian cancers.
Kwong A; Chen JW; Shin VY
Hong Kong Med J; 2016 Apr; 22(2):171-7. PubMed ID: 26980575
[TBL] [Abstract][Full Text] [Related]
8. Impact of Implementing B-RST
Wernke K; Bellcross C; Gabram S; Ali N; Stanislaw C
Clin Breast Cancer; 2019 Aug; 19(4):e547-e555. PubMed ID: 31005475
[TBL] [Abstract][Full Text] [Related]
9. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
Burke W; Daly M; Garber J; Botkin J; Kahn MJ; Lynch P; McTiernan A; Offit K; Perlman J; Petersen G; Thomson E; Varricchio C
JAMA; 1997 Mar; 277(12):997-1003. PubMed ID: 9091675
[TBL] [Abstract][Full Text] [Related]
10. Clinical considerations in the management of individuals at risk for hereditary breast and ovarian cancer.
Robson ME
Cancer Control; 2002; 9(6):457-65. PubMed ID: 12514563
[TBL] [Abstract][Full Text] [Related]
11. Hereditary breast and ovarian cancer: review and future perspectives.
Lux MP; Fasching PA; Beckmann MW
J Mol Med (Berl); 2006 Jan; 84(1):16-28. PubMed ID: 16283147
[TBL] [Abstract][Full Text] [Related]
12. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome.
Obstet Gynecol; 2009 Apr; 113(4):957-966. PubMed ID: 19305347
[TBL] [Abstract][Full Text] [Related]
13. Receiving inconclusive genetic test results: an interpretive description of the BRCA1/2 experience.
Maheu C; Thorne S
Res Nurs Health; 2008 Dec; 31(6):553-62. PubMed ID: 18449940
[TBL] [Abstract][Full Text] [Related]
14. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
15. [A new scoring system for the diagnosis of BRCA1/2 associated breast-ovarian cancer predisposition].
Bonaïti B; Alarcon F; Bonadona V; Pennec S; Andrieu N; Stoppa-Lyonnet D; Perdry H; Bonaïti-Pellié C;
Bull Cancer; 2011 Jul; 98(7):779-95. PubMed ID: 21708517
[TBL] [Abstract][Full Text] [Related]
16. Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer.
Antonucci I; Provenzano M; Sorino L; Balsamo M; Aceto GM; Battista P; Euhus D; Cianchetti E; Ballerini P; Natoli C; Palka G; Stuppia L
J Hum Genet; 2017 Mar; 62(3):379-387. PubMed ID: 27928164
[TBL] [Abstract][Full Text] [Related]
17. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
18. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
19. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
[TBL] [Abstract][Full Text] [Related]
20. [Experience at Sheba Hospital in oncogenetic counseling and genetic testing of women with a high risk for breast and ovarian cancer].
Theodor L; Shiri-Sverdlov R; Yechezkel GH; Bar-Sade RB; Gak E; Friedman I; Kruglikova A; Ben-Baruch G; Risel S; Papa MZ; Goldman B; Friedman E
Harefuah; 1998 Apr; 134(8):593-9, 672. PubMed ID: 10911419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]